低剂量雾化肾上腺素治疗哮吼的疗效:一项随机、安慰剂对照、双盲试验
该随机双盲非劣效试验在三个儿科急诊科进行,纳入6个月至5岁、Westley评分3-11分的中重度哮吼患儿,比较低剂量(0.1 mg/kg,最大1 mg)与常规剂量(0.5 mg/kg,最大5 mg)1:1000雾化左旋肾上腺素的疗效,所有患儿均接受0.6 mg/kg地塞米松。最终分析84例,两组30分钟哮吼评分均较基线显著降低(p<0.05),组间无显著差异(p=0.42),血压和心率也无组间差异。结论为低剂量不劣于常规剂量。
要点
- 中重度哮吼(Westley评分3-11分)患儿,低剂量0.1 mg/kg(最大1 mg)与常规0.5 mg/kg(最大5 mg)1:1000雾化左旋肾上腺素30分钟哮吼评分改善无显著差异(p=0.42)。
- 两组30分钟哮吼评分均较基线显著降低(p<0.05)。
- 两组血压和心率无差异。
- 所有患儿均接受0.6 mg/kg地塞米松。
- 低剂量1:1000左旋肾上腺素在哮吼评分降低方面不劣于常规剂量。
适用人群与场景
- 6个月至5岁、中重度哮吼(Westley评分3-11分)的患儿,在儿科急诊科就诊。
诊断标准与关键阈值
- 中重度哮吼定义为Westley评分3-11分。
处置流程与药物剂量
- 所有患儿接受0.6 mg/kg地塞米松。
- 随机接受常规剂量0.5 mg/kg(最大5 mg)或低剂量0.1 mg/kg(最大1 mg)1:1000雾化左旋肾上腺素。
- 在雾化左旋肾上腺素给药前及给药后30、60、90、120分钟测量哮吼评分和其他生命体征。
研究设计与关键结果
- 随机双盲非劣效试验,在三个儿科急诊科进行,2015年5月至2017年10月,最终分析84例。
- 主要终点为30分钟哮吼评分变化;两组30分钟评分均较基线显著降低(p<0.05),组间无显著差异(p=0.42)。
- 两组血压和心率无差异。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照非劣效试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于6个月至5岁、Westley评分3-11分的中重度哮吼患儿,低剂量0.1 mg/kg(最大1 mg)1:1000雾化左旋肾上腺素在30分钟哮吼评分改善上不劣于常规0.5 mg/kg(最大5 mg)剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Croup treatment usually involves a single dose of systemic dexamethasone combined with nebulized epinephrine. However, the optimal dose of l-epinephrine remains unclear. We examined whether a low dose (0.1 mg/kg) was inferior to the conventional dose (0.5 mg/kg) of 1:1000 nebulized l-epinephrine in patients with moderate to severe croup.
METHODS: This randomized double-blind clinical non-inferiority trial was conducted in three pediatric emergency departments from May 2015 to October 2017. Children 6 months to 5 years old with moderate to severe croup (Westley scale scores 3-11) were eligible. Subjects were randomly assigned to the conventional dose (0.5 mg/kg: maximum 5 mg) or low dose (0.1 mg/kg; maximum 1 mg) group. All subjects received 0.6 mg/kg dexamethasone. Croup scores and other vital signs were measured before and at 30, 60, 90, and 120 min after nebulized l-epinephrine administration. The primary outcome was the change in croup score after 30 min.
RESULTS: The final analysis included 84 patients. The groups did not differ significantly in terms of demographic parameters. At 30 min after treatment with nebulized l-epinephrine, the croup scores in both groups were significantly reduced from the baseline values (p < 0.05) and did not differ between the two groups (p = 0.42). Neither blood pressure nor heart rate differed between the two groups.
CONCLUSIONS: Low-dose 1:1000 l-epinephrine was not inferior in croup score reduction to the conventional dose in patients with moderate to severe croup. Clinical trial No: NCT01664507, KCT0002318.
参考来源
- Lee JH, Jung JY, Lee HJ, et al. Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial. Am J Emerg Med. 2019. PMID: 30878411. doi:10.1016/j.ajem.2019.03.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。